Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Journal of Gastroenterology|June 23, 2023
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional studyKatsuyoshi Matsuoka, Hajime Yamazaki, Masakazu Nagahori, et al.
Plos One|August 6, 2019
Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foamMakoto Naganuma, Fumihito Hirai, Kiyonori Kobayashi, et al.
Journal of Crohn'S & Colitis|August 28, 2016
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized TrialTakayuki Matsumoto, Satoshi Motoya, Kenji Watanabe, et al.
Journal of Gastroenterology|April 23, 2013
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's diseaseToshifumi Hibi, Atsushi Sakuraba, Mamoru Watanabe, et al.
Digestion|December 16, 2020
Questionnaire-Based Survey on Epidemiology of Functional Gastrointestinal Disorders and Current Status of Gastrointestinal Motility Testing in Asian CountriesTakeshi Kamiya, Satoshi Osaga, Eiji Kubota, et al.
Journal of Crohn'S & Colitis|February 13, 2019
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]Tadakazu Hisamatsu, Takayuki Matsumoto, Kenji Watanabe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2017
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's DiseaseKenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Adalimumab for the treatment of Japanese patients with intestinal Behçet's diseaseSatoshi Tanida, Nagamu Inoue, Kiyonori Kobayashi, et al.
Surgery Today|December 17, 2013
Risk factors for surgical site infection in Japanese patients with ulcerative colitis: a multicenter prospective studyToshimitsu Araki, Yoshiki Okita, Motoi Uchino, et al.
Journal of Human Genetics|June 19, 2015
Disease susceptibility genes shared by primary biliary cirrhosis and Crohn's disease in the Japanese populationYoshihiro Aiba, Keiko Yamazaki, Nao Nishida, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Journal of Gastroenterology|June 23, 2023
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional studyKatsuyoshi Matsuoka, Hajime Yamazaki, Masakazu Nagahori, et al.
Plos One|August 6, 2019
Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foamMakoto Naganuma, Fumihito Hirai, Kiyonori Kobayashi, et al.
Journal of Crohn'S & Colitis|August 28, 2016
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized TrialTakayuki Matsumoto, Satoshi Motoya, Kenji Watanabe, et al.
Journal of Gastroenterology|April 23, 2013
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's diseaseToshifumi Hibi, Atsushi Sakuraba, Mamoru Watanabe, et al.
Digestion|December 16, 2020
Questionnaire-Based Survey on Epidemiology of Functional Gastrointestinal Disorders and Current Status of Gastrointestinal Motility Testing in Asian CountriesTakeshi Kamiya, Satoshi Osaga, Eiji Kubota, et al.
Journal of Crohn'S & Colitis|February 13, 2019
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]Tadakazu Hisamatsu, Takayuki Matsumoto, Kenji Watanabe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2017
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's DiseaseKenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Adalimumab for the treatment of Japanese patients with intestinal Behçet's diseaseSatoshi Tanida, Nagamu Inoue, Kiyonori Kobayashi, et al.
Surgery Today|December 17, 2013
Risk factors for surgical site infection in Japanese patients with ulcerative colitis: a multicenter prospective studyToshimitsu Araki, Yoshiki Okita, Motoi Uchino, et al.
Journal of Human Genetics|June 19, 2015
Disease susceptibility genes shared by primary biliary cirrhosis and Crohn's disease in the Japanese populationYoshihiro Aiba, Keiko Yamazaki, Nao Nishida, et al.
Pageof 9